Consider a long position in Spruce Biosciences (SPRB), which is viewed as a high-conviction play with a potential price target of $500-$800 ahead of its planned FDA filing in Q1 2026. European biotech Abivax (ABVX) is also presented as a prime M&A target and a steady long-term investment, with a potential price of $200 per share. Conversely, investors should consider shorting or avoiding the quantum computing sector, specifically tickers like IONQ, QUBT, and RGTI, which are described as a speculative bubble. A contrarian opportunity may exist to short Advanced Micro Devices (AMD), as its recent OpenAI deal is viewed negatively with the stock potentially dropping below $200. For a shorter-term trade, Sarepta Therapeutics (SRPT) is a bullish idea that could reach $50 per share.

Spruce Biosciences (SPRB)

• The speaker is extremely bullish on Spruce Biosciences, calling it a "slam dunk for FDA approval." This conviction comes from his deep expertise in rare diseases, specifically lysosomal storage disorders (LSDs).
• The company has a drug for Sanfilippo syndrome, a rare and fatal genetic disorder. The clinical data shows the drug reduces the harmful substrate (heparan sulfate) to normal levels, which the speaker believes is sufficient for FDA approval.
• The FDA has confirmed that the biomarker used (heparan sulfate) could serve as the basis for accelerated approval, which is a major positive catalyst. The company plans to file for approval in Q1.
• The speaker compares SPRB to a past success story, Synergiva, which was acquired for $8 billion. He believes Spruce has the potential to become a billion-dollar company, despite its very small market cap at the time of the discussion (starting around $20-30 million).
• He notes that the drug was acquired from BioMarin (BMRN), a company known for sometimes selling off valuable assets that they deem too small for their portfolio. A similar situation occurred with Catalyst Pharmaceuticals (CPRX), which is now a multi-billion dollar company.

Takeaways

• Strong Bullish Thesis: The speaker presents a high-conviction long idea based on strong clinical data in a niche area he specializes in. The potential for FDA approval is seen as very high.
• Price Target: A price target of $500 to $800 per share is mentioned, with a high case of $1,000 if the company manages shareholder dilution effectively during its next capital raise.
• Catalysts: The primary upcoming catalyst is the filing for FDA approval in Q1 2026, followed by a potential approval later that year. The speaker believes that as Wall Street funds specializing in rare diseases discover the company, its valuation will increase significantly.
• Risks: The main risk mentioned is shareholder dilution. The company will need to raise cash, and the number of shares they sell will impact the ultimate share price. However, the speaker believes that even with significant dilution, the stock is massively undervalued. Manufacturing readiness for a commercial launch is also noted as a potential question mark, but not a deal-breaker for the stock's potential.

Quantum Computing Sector (IONQ, QUBT, RGTI, QBTS)

• The speaker is extremely bearish on the entire publicly traded quantum computing sector and is actively shorting all four major stocks: IonQ (IONQ), Quantum Computing Inc. (QUBT), Rigetti (RGTI), and D-Wave (QBTS).
• He describes the sector as a massive bubble and a "scam," comparing it to the 3D printing and Beyond Meat bubbles of the past. He believes the stocks will eventually go to zero.
• He specifically calls out QUBT as the "worst quantum name" because it has "no technology there... no assets, no business."
• He compares IonQ (IONQ) directly to Enron, suggesting significant fraud and misrepresentation. He dismisses the rising stock price as irrelevant, noting that Enron's stock also went up before it collapsed.
• The speaker's conviction is based on his knowledge of the technology and conversations with top people in the field, concluding that "it just doesn't add up." He believes the only reason the stocks are high is due to hype around a potential partnership with OpenAI, which he finds "odd."

Takeaways

• Strong Bearish Thesis: This is a high-conviction short thesis against the entire sector. The speaker views these companies as having no viable business model or technology and being fueled purely by speculation.
• Investment Action: The insight is to short or avoid stocks in the quantum computing space. The speaker is holding his short positions despite taking significant losses, believing the "quantum trade is ending" and cannot sustain itself.
• Risk Factor for Shorts: The primary risk, which the speaker is experiencing, is a "short squeeze." The stocks have been going up a lot, causing pain for short-sellers. He acknowledges that being early on a short can be financially painful, but remains convinced of the eventual outcome.

Advanced Micro Devices (AMD)

• The discussion centers on the major news of a strategic partnership between AMD and OpenAI. As part of the deal, OpenAI will purchase AMD's AI chips and, in return, receive warrants to acquire up to 10% of AMD's stock.
• The speaker's sentiment is surprisingly bearish for AMD. He calls the deal "Fugazi" (fake) and a "bribe for revenue."
• He believes AMD's CEO, Lisa Su, was desperate to get a deal with OpenAI and essentially gave away the GPUs for free. The structure allows AMD to book significant revenue, but it comes at the cost of giving away a massive amount of equity to its customer.
• He questions the strength of AMD's product, suggesting that if the chips were truly valuable, OpenAI would buy them without needing a 10% stake in the company as an incentive. He contrasts this with Jensen Huang (NVIDIA CEO), who he believes would never do such a deal.

Takeaways

• Bearish/Contrarian View: While the market initially reacted positively (stock was up), the speaker believes the deal is fundamentally bad for AMD shareholders and that the stock should be down.
• Price Prediction: He speculates that AMD stock could drop below $200 as the market digests the negative aspects of the deal structure.
• Actionable Insight: This is a contrarian take suggesting that the positive headline news masks a weak negotiating position for AMD. Investors should be wary of the "revenue growth" as it was effectively "bribed for" with equity.

Abivax (ABVX)

• The speaker is very bullish on Abivax, a European biotech company. He mentions it in the context of successful trades and future potential.
• The discussion highlights that Abivax has a very promising drug for ulcerative colitis (UC) and is a prime buyout/M&A target.
• The asset is described as having a "fit for purpose" drug with a high likelihood of success, making it a top-tier candidate for acquisition by a large pharmaceutical company.
• Even without a buyout, the stock is expected to "keep steadily marching up," with a chart that grinds higher over time.
• A price of $200 per share is mentioned as a possibility if the drug also shows success in Crohn's disease, which would expand its peak sales potential to over $5 billion.

Takeaways

• Bullish Thesis: A strong long idea based on a high-quality asset in the biotech space with a clear M&A catalyst.
• Investment Action: The insight is to be long ABVX, as it is seen as undervalued with multiple ways to win (steady appreciation or a buyout). The speaker suggests that any dips are buying opportunities.
• Potential Acquirers: Several large pharma companies are mentioned as potential suitors, including Johnson & Johnson, Sanofi, and Lilly, indicating broad interest is likely.

AI Sector & OpenAI

• The speaker is generally bullish on the AI sector, differentiating it from speculative bubbles like quantum computing. He states that "AI has value" and is already a monetizable industry generating tens of billions in revenue.
• The transcript includes a lengthy broadcast of OpenAI's Dev Day, which showcases significant progress and new tools, reinforcing the bullish theme.
• Key OpenAI Announcements:
  • Apps SDK: Allows developers to build full, interactive apps directly inside of ChatGPT, with potential for monetization and distribution to hundreds of millions of users.
  • Agent Kit: A full suite of tools (Agent Builder, Chat Kit, Evals) to make it easier for developers to build, deploy, and optimize AI agents.
  • Codex GA: OpenAI's AI coding assistant is now generally available and integrated into team workflows like Slack, with a new, more powerful GPT-5 Codex model.
  • New Models in API: GPT-5 Pro (their most intelligent model) and Sora 2 (advanced text-to-video with sound) are being released in the API for developers.

Takeaways

• Ecosystem Growth: The announcements from OpenAI are designed to dramatically accelerate development on its platform, making it easier for businesses and individuals to build with AI. This is bullish for the entire AI ecosystem.
• Investment Theme: While OpenAI is private, its growth is a massive driver for its partners. This includes cloud providers and especially chip makers like NVIDIA and AMD who supply the necessary computing power. The insatiable demand for "compute" was a recurring theme.
• Future of Software: The advancements in Codex signal a fundamental shift in how software is created, moving towards AI-assisted and agentic coding, which could dramatically increase developer productivity.

Short Ideas (MNPR, CAPR, AVXL)

• The speaker identifies several biotech stocks that he is actively shorting or considers to be good short candidates.
• Monopar Therapeutics (MNPR): He is bearish, stating their main drug is "garbage." He considers it a "shorter."
• Capricor Therapeutics (CAPR): He is bearish, stating "Capper is a short."
• Anavex Life Sciences (AVXL): He is extremely bearish, calling it "Scam of X" and "one of the worst drug companies ever." He claims its drug is "not real" and will not get approval.

Takeaways

• Bearish Conviction: The speaker has strong negative opinions on these specific biotech companies, believing their science or business models are flawed.
• Actionable Insight: These are presented as specific short ideas for investors with a high risk tolerance and an interest in the biotech sector.

Other Stock Mentions

• NVIDIA (NVDA): The speaker does not believe the AMD/OpenAI news is bearish for NVIDIA. He notes the stock was nearly flat on the news, suggesting the market sees NVIDIA's dominant position as unshaken.
• Sarepta Therapeutics (SRPT): The speaker is bullish, stating he "still likes" the stock and believes it "should be able to get $50 pretty easily."
• AnaptysBio (ANAB): The speaker is bullish, calling it "very, very exciting." He highlights its royalty stream from a deal with GSK but also notes a history of wasting money. He added it to his long list.
• Novo Nordisk (NVO) & Eli Lilly (LLY): Mentioned briefly in the context of weight-loss drugs. The speaker believes the entire space is facing demand issues and that LLY seems to be outperforming NVO.